Davis R M Inc. Has $26.01 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Davis R M Inc. grew its holdings in Zoetis Inc. (NYSE:ZTS) by 0.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 133,115 shares of the company’s stock after acquiring an additional 805 shares during the period. Davis R M Inc.’s holdings in Zoetis were worth $26,008,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ZTS. Darwin Wealth Management LLC acquired a new position in Zoetis during the third quarter worth $31,000. First Personal Financial Services bought a new stake in shares of Zoetis during the 3rd quarter worth about $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis during the 3rd quarter valued at about $33,000. Quarry LP increased its holdings in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the last quarter. Finally, Fortitude Family Office LLC raised its stake in shares of Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after acquiring an additional 222 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.1 %

Shares of NYSE ZTS opened at $176.96 on Monday. The business has a fifty day moving average of $185.62 and a two-hundred day moving average of $180.72. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The stock has a market cap of $79.84 billion, a PE ratio of 33.26, a PEG ratio of 2.71 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the company earned $1.36 EPS. Zoetis’s revenue for the quarter was up 11.6% on a year-over-year basis. As a group, equities research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ZTS. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus lifted their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. BTIG Research boosted their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler raised their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.